187 related articles for article (PubMed ID: 14713978)
1. [Pulmonary arterial hypertension treated with prostacyclin or calcium blockers].
Andreassen AK; Geiran O; Madsen S; Hognestad A; Simonsen S
Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3393-6. PubMed ID: 14713978
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
[TBL] [Abstract][Full Text] [Related]
4. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
5. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
Nakayama T; Ishikita T; Matsuura H; Saji T
J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
[TBL] [Abstract][Full Text] [Related]
6. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
7. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
[TBL] [Abstract][Full Text] [Related]
8. [Nebulized prostacyclin treatment for pulmonary hypertension in a 2-year-old girl].
Puigarnau Vallhonrat R; Pons Odena M; Carballo Ruano E
An Esp Pediatr; 2000 Oct; 53(4):372-6. PubMed ID: 11083992
[TBL] [Abstract][Full Text] [Related]
9. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
Stricker H; Domenighetti G; Fiori G; Mombelli G
Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
[TBL] [Abstract][Full Text] [Related]
10. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
Sitbon O; Humbert M; Jaïs X; Ioos V; Hamid AM; Provencher S; Garcia G; Parent F; Hervé P; Simonneau G
Circulation; 2005 Jun; 111(23):3105-11. PubMed ID: 15939821
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in children with idiopathic pulmonary arterial hypertension.
Yung D; Widlitz AC; Rosenzweig EB; Kerstein D; Maislin G; Barst RJ
Circulation; 2004 Aug; 110(6):660-5. PubMed ID: 15289375
[TBL] [Abstract][Full Text] [Related]
12. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
13. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
14. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
[TBL] [Abstract][Full Text] [Related]
15. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G
Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982
[TBL] [Abstract][Full Text] [Related]
16. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ
J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients.
Khan TA; Schnickel G; Ross D; Bastani S; Laks H; Esmailian F; Marelli D; Beygui R; Shemin R; Watson L; Vartapetian I; Ardehali A
J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1417-24. PubMed ID: 19931670
[TBL] [Abstract][Full Text] [Related]
18. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).
Klings ES; Hill NS; Ieong MH; Simms RW; Korn JH; Farber HW
Arthritis Rheum; 1999 Dec; 42(12):2638-45. PubMed ID: 10616012
[TBL] [Abstract][Full Text] [Related]
19. [Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy].
Uchi M; Saji T; Harada T
J Cardiol; 2005 Nov; 46(5):183-93. PubMed ID: 16320975
[TBL] [Abstract][Full Text] [Related]
20. Epoprostenol treatment in children with severe pulmonary hypertension.
Lammers AE; Hislop AA; Flynn Y; Haworth SG
Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]